Market Cap 248.83M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 35,800
Avg Vol 41,820
Day's Range N/A - N/A
Shares Out 6.12M
Stochastic %K 14%
Beta 1.05
Analysts Strong Sell
Price Target $57.50

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:11 PM
$MNPR Excellent article that nails exactly where MNPR stands right now. So if you want to update your MNPR knowledge or get acquainted with MNPR, this is a must read. https://beyondspx.com/article/monopar-therapeutics-a-dual-pipeline-bet-on-rare-disease-and-radiopharmaceuticals-nasdaq-mnpr
0 · Reply
IsabellaDC
IsabellaDC Jul. 29 at 4:52 PM
Swing trades possible with these RUSS stocks. Be patient with your entries. $QUBT $QBTS $PRCH $SEZL $MNPR and so on.
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 25 at 6:41 PM
Australian radiopharmaceutical market is hot Clarity Pharmaceuticals market cap just tripled to $920 million and Telix Market cap is $4.7 billion. Makes Radiopharma Theranostics looks very cheap at $35 million market cap. Imaging data out soon could be next big winner. $RADX $MNPR $LNTH $IOVA
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 20 at 2:45 PM
Her2 Lu-177 is showing 30-40% responses in other similar trials. Should provide great upside to RADX 3q data $RADX $LNTH $MNPR
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 18 at 2:34 PM
$CYCN there's a group of about 5 or 6 us longs in here that own over 10% of the company collectively, the former CEO and current chairman of the board, Peter Hecht, owns 30% himself. Other insiders own around 10%. Tutes then own another 20-30%. This thing has very little free float so when the news hammer gets dropped (any day now), this thing will be of epic proportions. Think $DRUG or $MNPR type move IMO
0 · Reply
IanMaui
IanMaui Jul. 18 at 1:47 PM
$MNPR back to $50! Still a holder!
0 · Reply
stockbott
stockbott Jul. 17 at 9:08 PM
$MNPR going up. 50$
0 · Reply
Doozio
Doozio Jul. 17 at 6:45 PM
$MNPR until they weren’t. Bahhht out of🐑⏰♾️ they are. 🐒🍌🧠⏰♾️
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 10 at 4:09 PM
$RADX Only 4K borrow could explode at any time in Radiopharm Theranostics $MP $NNE $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 8 at 6:42 PM
$RADX Trading at $4.00 And that’s a $7.70 discount to what Lantheus just paid in January. https://m.youtube.com/watch?v=OjzgnRS7b98 $MNPR $NNE
0 · Reply
Latest News on MNPR
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 3 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025


Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule


Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split


Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration


Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession


Monopar to Present at the 35th Annual Roth Conference

Mar 7, 2023, 7:00 AM EST - 2 years ago

Monopar to Present at the 35th Annual Roth Conference


NVDAMillionaire
NVDAMillionaire Jul. 29 at 6:11 PM
$MNPR Excellent article that nails exactly where MNPR stands right now. So if you want to update your MNPR knowledge or get acquainted with MNPR, this is a must read. https://beyondspx.com/article/monopar-therapeutics-a-dual-pipeline-bet-on-rare-disease-and-radiopharmaceuticals-nasdaq-mnpr
0 · Reply
IsabellaDC
IsabellaDC Jul. 29 at 4:52 PM
Swing trades possible with these RUSS stocks. Be patient with your entries. $QUBT $QBTS $PRCH $SEZL $MNPR and so on.
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 25 at 6:41 PM
Australian radiopharmaceutical market is hot Clarity Pharmaceuticals market cap just tripled to $920 million and Telix Market cap is $4.7 billion. Makes Radiopharma Theranostics looks very cheap at $35 million market cap. Imaging data out soon could be next big winner. $RADX $MNPR $LNTH $IOVA
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 20 at 2:45 PM
Her2 Lu-177 is showing 30-40% responses in other similar trials. Should provide great upside to RADX 3q data $RADX $LNTH $MNPR
1 · Reply
skyrockets_Inc
skyrockets_Inc Jul. 18 at 2:34 PM
$CYCN there's a group of about 5 or 6 us longs in here that own over 10% of the company collectively, the former CEO and current chairman of the board, Peter Hecht, owns 30% himself. Other insiders own around 10%. Tutes then own another 20-30%. This thing has very little free float so when the news hammer gets dropped (any day now), this thing will be of epic proportions. Think $DRUG or $MNPR type move IMO
0 · Reply
IanMaui
IanMaui Jul. 18 at 1:47 PM
$MNPR back to $50! Still a holder!
0 · Reply
stockbott
stockbott Jul. 17 at 9:08 PM
$MNPR going up. 50$
0 · Reply
Doozio
Doozio Jul. 17 at 6:45 PM
$MNPR until they weren’t. Bahhht out of🐑⏰♾️ they are. 🐒🍌🧠⏰♾️
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 10 at 4:09 PM
$RADX Only 4K borrow could explode at any time in Radiopharm Theranostics $MP $NNE $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 8 at 6:42 PM
$RADX Trading at $4.00 And that’s a $7.70 discount to what Lantheus just paid in January. https://m.youtube.com/watch?v=OjzgnRS7b98 $MNPR $NNE
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 8:28 PM
Cantor Fitzgerald has updated their rating for Monopar Therapeutics ( $MNPR ) to Overweight with a price target of 74.
0 · Reply
JarvisFlow
JarvisFlow Jun. 23 at 11:00 AM
Chardan Capital has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 60.
0 · Reply
wavess
wavess Jun. 18 at 6:29 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has activated its second clinical site in France for the Phase 2 trial of TTI-0102, a next-gen thiol-based therapy for MELAS—a rare and devastating mitochondrial disease: https://x.com/StckMasterFlash/status/1935049659816214802 On track for key data readouts by September 2025, this expansion highlights both the growing momentum behind TTI-0102 and the strategic advantage of conducting trials in Europe’s increasingly efficient regulatory landscape for orphan diseases, over the US FDA. $MNPR $XENE
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 16 at 9:49 PM
Revolutionizing cancer treatment with first in class Radiopharmaceutical’s https://radiopharmtheranostics.com $CATX $RADX $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 13 at 2:41 PM
$RADX Monopar 2.0 $MNPR
0 · Reply
Hereinbama35
Hereinbama35 Jun. 11 at 4:55 PM
$ATYR $DRUG $MNPR I wish someone would have told me ahead of time. 😒
1 · Reply
Houzehero
Houzehero Jun. 11 at 4:03 PM
$ATYR A couple of biotechs that went parabolic last year: $DRUG gained 1,445% and $MNPR gained 600% in Single Day Trading sessions and both were in October.
0 · Reply
davis8uni
davis8uni Jun. 11 at 11:17 AM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 11 at 11:13 AM
$MNPR Monopar Therapeutics, EDNOC announce EAP for MNPR-101-Zr, MNPR-101-Lu Monopar Therapeutics in collaboration with Excel Diagnostics and Nuclear Oncology Center, EDNOC, a premier diagnostic medical imaging and therapeutic nuclear medicine center, announced that the physician-sponsored Expanded Access Program, EAP, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration. "We are pleased to provide patients in the United States with access to MNPR-101-Zr and MNPR-101-Lu, which were developed to target aggressive cancers, such as triple-negative breast, pancreatic, and colorectal cancer," said Andrew Cittadine, Chief Operating Officer of Monopar. "This EAP represents continued progress in our radiopharmaceutical pipeline following last year's initiation of Phase 1 clinical trials in Australia with MNPR-101-Zr and MNPR-101-Lu. We are grateful for the opportunity to work with Dr. Delpassand to make these therapies available to patients on a compassionate use basis," added Cittadine.
0 · Reply
biospeculator
biospeculator Jun. 9 at 5:39 PM
$MNPR Hmmmm. Does MNPR do a secondary in order to meet liquidity requirements to join the Russell 2000 and have options as well?
0 · Reply
SirBensonNaija
SirBensonNaija Jun. 6 at 1:19 AM
$MNPR long
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 4 at 12:28 PM
$RADX Radiopharma heating up.. $LNTH just bought more at $11.7 usd owns12%.. tiny $40 mil mkt cap $CATX $MNPR $ADCT
0 · Reply